glp 1 agonist comparison chart Comparing GLP-type therapies for weight loss in those without diabetes. Two glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (#semaglutide and #liraglutide) and one dual (#tirzepatide) have been FDA-approved for #weightloss in adults The Weight-loss Effect of GLP-1RAs

Novo Nordisks strong clinical data and successful commercialization of its GLP-1 receptor agonist portfolio have established it as a market leader

Adverse effects Most people are able to tolerate DPP-4 inhibitors fairly well

One of the other oral GLP-1s on the horizon, Pfizers danuglipron pill, led to a similar weight loss as injectable semaglutide according to results recently released from Phase 2 clinical trials

Footnotes Conflict-of-interest statement: The authors have no conflicts of interest to declare

Discussion Major findings Our MR analysis demonstrated that genetically proxied GLP-1RAs are causally associated with a reduced risk of AF, cardiac arrest, and ventricular fibrillation

Key Takeaway GLP-1 drugs, such as Wegovy and Ozempic, could potentially disrupt various areas of the economy